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Cardiovascular and mitochondrial disordersMitochondria are crucial in different intracellular pathways of signal transduction. Mitochondria are capable
of decoding a variety of extracellular stimuli intomarkedly different intracellular actions, ranging from energy
production to cell death. The ﬁne modulation of mitochondrial calcium (Ca2+) homeostasis plays a
fundamental role in many of the processes involving this organelle. When mitochondrial Ca2+ homeostasis is
compromised, different pathological conditions can occur, depending on the cell type involved. Recent data
have shed light on the molecular identity of the main proteins involved in the handling of mitochondrial Ca2+
trafﬁc, opening fascinating and ambitious new avenues for mitochondria-based pharmacological strategies.
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It is now ﬁrmly established that mitochondria are key players in
different pathophysiological contexts (Duchen, 2004). Indeed, they
are very efﬁcient machines for decoding intracellular signals and in
particular the calcium (Ca2+) one (Clapham, 2007).
Themitochondrial respiratory chain, by pumping protons across the
ion-impermeable inner membrane, establishes a gradient (ΔμH),
composed of an electrical potential (Δψ) and a concentration ratio
(ΔpH), according to the Nernst equation: ΔμH=zFΔψ+RT lnntal and Diagnostic Medicine,
ara, Italy.
arch Society. Open access under CC B[H+]i/[H+]o. This has major implications for Ca2+ transport and
distribution. In actively respiring mitochondria, considering that the
buffering capacity is mostly provided by weak acids, the gradient is
supposed to be maintained mostly as an electrical gradient across the
inner membrane (~180 mV). This implies a strong thermodynamic
force in favor of the accumulation of cations (Rizzuto et al., 2000).
Ca2+ import across the outer mitochondrial membrane (OMM)
occurs through the voltage-dependent anion channels (VDAC)
(Simamura et al., 2008). VDAC is as a large voltage-gated channel,
fully opened with high-conductance and weak anion-selectivity at
low transmembrane potentials (b20–30 mV), but switching to cation
selectivity and lower conductance at higher potentials (Colombini,
2009; De Pinto et al., 2008; Shoshan-Barmatz et al., 2010). The precise
mechanisms of VDAC conductance are however still under debate.Y-NC-ND license.
Fig. 1. Mitochondrial physiology and mitochondrial Ca2+ handling. Ca2+ enters in the
mitochondrial matrix via a low afﬁnity uniporter (MCU) and through a high
electronegative potential (−180 mV). Extrusion of Ca2+ takes two major routes, one
driven by the Na+/Ca2+ exchanger, and another pathway which involves H+–Ca2+
exchanger. In the matrix, Ca2+ stimulates the activity of three Ca2+-sensitive de-
hydrogenases of the Krebs cycle. The gradient across the innermembrane is important for
the mitochondrial state and is established by the activity of the mitochondrial respiratory
chain. VDAC: voltage-dependent anion channel, ANT: adenosine nucleoside transporter,
HK: hexokinase, CD: cyclophilin D, CK: creatine kinase, BR: benzodiazepine receptor, PTP:
permeability transition pore.
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brane (IMM) takes place essentially through two pathways: i) an
electrophoretic “uniporter” that transports Ca2+ down the electrical
gradient established by the respiratory chain, and ii) a Na+/Ca2+
exchanger,mostly expressed in excitable cells (muscle and brain), and a
H+/Ca2+ exchanger, that represents the prevailing route in most other
tissues (see Fig. 1). These electroneutral antiporters prevent the
attainment of an electrochemical equilibrium (Rizzuto et al., 2000).
Despite intense investigations on the mitochondrial Ca2+ uniporter
(MCU) for almost 50 years, the molecular identity of this gated channel
is still a matter of debate. Among the early candidates for theMCUwere
mitochondria-localized RyR1 (Beutner et al., 2005) and the uncoupling
proteins (UCP) 2 and 3 (Trenker et al., 2007), but such a role for these
proteins is still controversial and further work will be needed to
deﬁnitively elucidate the molecular identity of the channels or carriers
involved. The identity of the MCU, as the product of the ccdc109a gene,
has recently been reported by two recent publications (Baughman et al.,
2011; De Stefani et al., 2011). In that respect, the report that the IMM
protein leucine-zipper-EF hand-containing transmembrane region
(Letm1), previously described as a K+/H+ exchanger (Nowikovsky
et al., 2004), could be aCa2+/H+antiporter, catalyzing the uptake of Ca2+
into mitochondria was received with great interest (Jiang et al., 2009).
These results remain a subject of intense discussion because they
diverge in several issues from previous studies; in particular, the effect
of Letm1 down-regulation/over-expression on mitochondrial Ca2+
transport could be a secondary effect of a decreased K+/H+ exchange
activity. Finally, it is important to mention the recent description of anIMM Ca2+-binding protein named mitochondrial calcium uptake 1
(MICU1), which appears essential for mitochondrial Ca2+ uptake
(Perocchi et al., 2010). MICU1 is a single-pass transmembrane protein
and thus does not seem to participate in channel pore formation. It is
possible that MICU1 is part of a complex with the mitochondrial Ca2+
channel, or functions as Ca2+ buffer, or as a Ca2+-dependent regulatory
protein acting as a Ca2+ sensor (through a pair of Ca2+-binding EF-hand
domains present in its sequence, the mutation of which eliminates the
mitochondrial Ca2+ uptake).
About the systemformitochondrial Ca2+extrusion, themitochondrial
Na+/Ca2+ exchanger (mNCX) and H+/Ca2+ exchanger (mHCX), have
well known kinetic characteristics, are present in the IMM (Bernardi,
1999b). Recently, strong evidence has been provided that the Na+/Ca2+
exchanger isoform NCLX is the long-sought protein responsible for the
mitochondrial Na+-dependent Ca2+ efﬂux (Palty et al., 2010).
Moreover, great attention has been drawn to the potential role of a
large-conductance channel, commonly referred to as the permeability
transition pore (PTP). It is supposed to be a multiprotein complex
activated in various pathophysiological conditions (e.g., mitochondrial
Ca2+ overload) (see Fig. 1). Its role in mitochondrial Ca2+ homeo-
stasis, however, remains elusive (Bernardi and Forte, 2007).
In a variety of cell systems (ranging from epithelial cells to
neurons), the cytosolic [Ca2+] ([Ca2+]c) rises evoked by physiological
stimulations are always paralleled by rapid mitochondrial [Ca2+]
([Ca2+]m) increases, that reach values well above those of the bulk
cytosol (up to ~500 μM in chromafﬁn cells) (Giorgi et al., 2009).
A Ca2+ signal originating in the cytoplasm that is propagated to
mitochondria permits the transmission of an activatory signal to the
energy powerhouse of the cell. Here, three key metabolic enzymes
(pyruvate,α-ketoglutarate, and isocitratedehydrogenases) are activated
by Ca2+. Thus, in conjunction with the triggering of energy-consuming
processes in the cytosol (contraction, secretion, etc.), mitochondrial
dehydrogenases are stimulated, adapting aerobic metabolism to the
increased energy needs of an active cell (Rimessi et al., 2008).
A completely different role for mitochondrial Ca2+ uptake is now
well recognized. The alteration of the Ca2+ signals that reach
mitochondria in association with different pathological conditions
(e.g., oxidative stress) can induce a profound alteration of organelle
structure and function. As a consequence, the cell may be driven to its
death (Giorgi et al., 2008).
Here, we review some human diseases associated with perturba-
tions in mitochondrial homeostasis with particular emphasis on the
role of Ca2+ signals.
2. Mitochondria and aging
Aging is not considered as an adaptative response, but rather as the
price of other evolutionary selected functions, currently not completely
speciﬁed (Kirkwood and Austad, 2000). This degeneration is character-
izedby aprogressive lossof organ function, proposed tobeat the basis of
several degenerative disorders, promoted by a progressive occurrence
of apoptosis in non-proliferating cells. It was recognized that mito-
chondrial ATP synthesis is associated with reactive oxygen species
(ROS) production, including primarily superoxide (O2−) formation by
the respiratory chain complexes I and III (Balaban et al., 2005; Raha and
Robinson, 2000). Subsequently, superoxide leads to the formation of
diverse oxidant products, such as peroxynitrite, hydrogen peroxide
(H2O2) and the highly reactive hydroxyl radical (OH). Mitochondria are
considered themajor source of ROS and the extent of oxidative damage
to macromolecules is generally thought to be the random consequence
of physiological functions, as exempliﬁed by lipid peroxidation, protein
oxidation, and mitochondrial DNA mutations (Cadenas and Davies,
2000). Different works on the molecular routes of apoptosis have
revealed the important role of mitochondria in decoding of oxidative
insults, with the release of proteins such as cytochrome c (cyt c) or
Smac/Diablo,which act as co-factors of effector caspases. Ca2+overload,
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the PTP and swelling of the organelle in what appears to be a pivotal
pathway (Duchen, 2000; Ravagnan et al., 2002).
One important implication of recent ﬁndings is that these phenom-
ena are genetically determined at least in part and biochemically
controlled by a stress-induced signal transduction pathway involving the
66-kDa isoform of Shc, p66Shc. The relationship between mitochondria
and p66Shc emerged once the protein was effectively localized to the
organelle and by the observation that, upon oxidative stress, part of the
cytosolic pool of p66Shc translocates to mitochondria (Orsini et al.,
2004). The protein lacks a conventional mitochondrial targeting
sequence, but its association with the mitochondrial TOM/TIM import
complex and the mitochondrial heat shock protein mtHsp70 has been
reported (Orsini et al., 2004). Within mitochondria, in particular in the
mitochondrial intermembrane space, p66Shc binds cyt c and acts as a
redox-enzyme, generating H2O2, which, in turn, induces the opening of
the PTP and apoptosis. ROS production by p66Shc appears to be a
specialized function whereby electrons are diverted from the mitochon-
drial electron transport chain to catalyze the partial reduction of
molecular oxygen (Giorgio et al., 2005). Furthermore, the CH2 domain
of p66Shc (a speciﬁc N-terminus domain that distinguishes p66Shc from
the shorter Shc isoforms, p46 and p52) seems to form a redox module
responsible for apoptosis initiation, and can be activated through
reversible tetramerization by forming two disulﬁde bonds (Donoghue
et al., 1990). The redox activity of p66Shc is likely to be theexplanation of
the decrease in ROS levels typical of p66Shc knockout cells (Migliaccio
et al., 2006), as well as an altered mitochondrial metabolism,
characterized by lower oxygen consumption under basal conditions
(Nemoto et al., 2006). To exert its functions, p66Shc has to be
phosphorylated at Serine 36 (Migliaccio et al., 1999): the responsible
kinase was identiﬁed as PKCβ (Pinton et al., 2007). This phosphoryla-
tion of Ser36 induces translocation of phosphorylated p66Shc to
mitochondria, and both H2O2 challenge and PKCβ activation promote
binding of p66Shc to Pin1, causing this translocation (Pinton et al.,
2007). The enzymatic activity of Pin1 is fundamental because the
phosphorylated sites, once isomerized by Pin1, become targets for
dephosphorylation by PP2A (Wulf et al., 2005). This solves the apparent
paradox showing the importance of p66Shc phosphorylation and the
dephosphorylated state of p66Shc within mitochondria. Thus, the
signaling pathway involving PKCβ, Pin1 and PP2A controls the
mitochondrial import of p66Shc where the translocated protein can
exert its oxidoreductase activity, generating H2O2 and inducing the
opening of the PTP. All these events are ﬁnely linked to an altered
mitochondrial Ca2+ homeostasis, revealing a primary mitochondrial
perturbation both in structure and function. In fact, oxidative stress
causes a drastic reduction of [Ca2+]m in MEF cells, whereas knockouts
for p66Shc or Pin1 are mostly insensitive to H2O2 treatment. Moreover,
the simple over-expression of PKCβ induces a strong decrease of
mitochondrial Ca2+ uptake, underlining how mitochondrial Ca2+
alteration is one of the ﬁrst events of oxidoreductase activity of p66Shc.
Translocation of p66Shc to mitochondria is a characteristic event of
some kinds of tumors, such as prostate cancer. MEF cells from p66Shc
knockout mice were more resistant to PEITC (an apoptosis-inhibitor)
and the same treatment increased both Ser36 phosphorylation and
p66Shc-Pin1 binding in PC-3 and LNCaP human cancer prostate cells
(Xiao and Singh, 2010). Moreover, growth stimulation of prostate
cancer cells with 5α-dihydrotestosterone (DHT) is accompanied by
increased p66Shc levels, ROS production, translocation of p66Shc into
mitochondria and an augmented interaction with cyt c (Veeramani
et al., 2008).
3. Mitochondria and neurodegenerative diseases
Among other deleterious consequences described in this article,
mitochondrial impairment has also been associated with the patho-
genesis of some neurodegenerative and neuroinﬂammatory disorders.Many lines of evidence suggest that bothmitochondrial DNAmutations
and increased oxidative stress are major contributors in aging — a
process rendering the organism prone to neurodegeneration. Particu-
larly interesting, it has been demonstrated in many of the most
frequently occurring diseases that mitochondria interact with proteins
crucial to the development the pathology. In these interactions, Ca2+
homeostasis often plays a key role (see Fig. 2). This brings hope for
effective therapies that target mitochondrial processes and interaction
sites of mitochondria and disease-related proteins.
The most frequent age-related neurodegenerative disorder –
Alzheimer's disease (AD) – is manifested by an impairment in cognitive
abilities, particularly responsible for memory functions. At the molec-
ular level, AD pathogenesis is associated with the accumulation of a
number of proteins, including reelin and presenilins, which leads to the
overproduction of β-amyloid (Aβ). Aggregated amyloid plaques and
neuroﬁbrillary tangles are considered a sign of AD. The β-amyloid
toxicity is further supported by the inability of neurons to properly
regulate intracellular Ca2+ levels (Mattson, 2007; Thibault et al., 2007).
Harmful consequences of Aβ activity include increased Ca2+ inﬂux into
neurons, rendering them prone to excitotoxicity and apoptosis
(Bezprozvanny and Mattson, 2008). Also the interaction of Aβ with
other cations, such as Fe2+ and Cu2+, leads to the generation of OH
which causes membrane lipid peroxidation and, in turn, impairs the
function of plasma membrane Ca2+ ATPase (PMCA), a Ca2+ pump
responsible for Ca2+ extrusion from the cell interior to the extracellular
compartment. Moreover, lipid peroxidation due to destabilization of
membrane composition causes depolarization of plasmamembraneand
leads to the opening of NMDAR and voltage-gated Ca2+ channels,
additionally intensifying an inﬂux of toxic amounts of Ca2+ into the
cytoplasm (Berridge, 2010). Finally, mutants of presenilins lower the
[Ca2+] of intracellular storeby increasingCa2+ leakage and reducingCa2+
uptake (Brunello et al., 2009).
Ca2+ homeostasis can also be affected by ROS due to the deterioration
of membranes forming the intracellular Ca2+ stores (e.g., endoplasmic
reticulum, ER). It has also been demonstrated that Aβ accumulates in
mitochondria decreasing the activity of complexes III and IV of the
respiratory chain (Anandatheerthavarada and Devi, 2007). Through such
a decrease in mitochondrial function, Aβ propels a vicious cycle in which
an elevation in cytosolic Ca2+ levels, oxidative stress, and decreased ATP
synthesis, all induce a further Ca2+overload and an even higher oxidative
stress (Lin and Beal, 2006). Taken together these ﬁndings indicate that
suppressionorblockingofCa2+ inﬂuxcould ineffectpromote the survival
of degenerating neurons. Several preliminary trials of L-type Ca2+ and
NMDAR channel blockers have been carried out with some success;
however, crucial obstacles still need to be overcome before the therapy
can be considered successful (Mattson, 2007).
Themost frequentmovement disorder – Parkinson's disease (PD) – is
caused by widespread neurodegeneration in the brain and a signiﬁcant
selective loss of nigrostriatal dopaminergic neurons (Thomas and Beal,
2010). ProcessesunderlyingPDpathogenesis, especially in itsnon-familial
occurrence, remain unclear. In both cases, PD pathogenesis is associated
with mitochondrial degeneration. The engagement of L-type Ca2+
channels is crucial in spontaneous pacemaking (Hausser et al., 2004),
while at the same time it may contribute to elevated toxicity of
mitochondrial toxins to nigrostriatal dopaminergic neurons. In this
way, Ca2+ homeostasis is a regulator of their selective vulnerability
(Chan et al., 2009; Surmeier et al., 2010). It has been proposed that
the reduction in expression of the transient receptor potential cation
(TRPC1) channel may be involved in dopaminergic neurodegeneration.
TRPC1 could also be neuroprotective against PD-inducing agents
(Bollimuntha et al., 2005).
A progressive neurodegenerative disorder – Huntington's disease
(HD) – is characterized by severe motor, cognitive, and psychiatric
symptoms. The genetic etiology of HD has been established to be a
CAG-triplet mutation within the huntingtin gene, inherited in an
autosomal dominant fashion. Possible links between mitochondrial
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have been recently reviewed (Celsi et al., 2009).
Another frequent neurological disorder potentially associatedwith
mitochondrial dysfunctions and Ca2+ signaling is epilepsy. A number
of authors report that this disease, prevalently initiated by neurolog-
ical insults, is related to shifts in Ca2+ homeostasis. An increase in
extracellular glutamate concentration sustains long-term distortions
in Ca2+ signaling, a characteristic recognized as the epileptic
phenotype (Delorenzo et al., 2005; Nagarkatti et al., 2009). A number
of mitochondrial, as well as nuclear, DNA mutations have been
implicated with epileptic phenotypes. Changes in electron transport
chain activity increase metabolic demand in neurons and lead to
distortions in Ca2+ homeostasis increasing its dendritic level.
4. Mitochondrial diseases
The number and distribution of mitochondria varies from one tissue
to another, depending from the tissue's dependence on oxidative
phosphorylation for energy provision. For this reason, Mitochondrial
Diseases (MIDs) predominantly manifest themselves in tissue/organs
with high-energy requirements, and are aggravated by fever, infection,
stress, toxic agents, or certain drugs (Finsterer, 2006).
MIDs aremainly due tomutations inmitochondrial or nuclear DNA
(mtDNA and nDNA, respectively), resulting in the altered function of
the respiratory chain or oxidative phosphorylation (OXPHOS)
(Reinecke et al., 2009).
The respiratory chain machinery consists of approximately 80
proteins, of which 13 are encoded by mtDNA and all others are
encoded by nDNA (DiMauro, 2004; Finsterer, 2010).
Interplaybetween themitochondrial andnuclear genomes is evident
in disorders of nuclear- and mtDNA-encoded subunits of the OXPHOS
complexes (Smeitink et al., 2001). Deﬁciencies in OXPHOS result in
immediate anddownstreammetabolic, structural, and functional effects.
These effects are closely associatedwithmitochondrial dysfunction. ATP
production, and consequently ATP/ADP homeostasis, is disturbed in
OXPHOS deﬁciencies (Smeitink et al., 2006).
The mitochondrial genome possesses a very high mutation rate,
10- to 17-fold higher than that observed in nDNA. Protective histones
are also lacking, and although mtDNA repair systems do exist (de
Souza-Pinto et al., 2009), they are not sufﬁcient to counteract the
oxidative damage sustained by the mitochondrial genome (Tuppen et
al., 2010). At the same time, pathogenic nDNA mutations are likely to
be more numerous than pathogenic mtDNA mutations (Finsterer,
2010). Point mutations have been correlated with numerous diseases,
such as Leigh syndrome, Barth syndrome, neuropathies, cardiomyop-
athies, hepatopathy, nephropathy, multisystemic disease, and neuro-
degenerative diseases, including PD, AD and amyotrophic lateral
sclerosis. (DiMauro, 2004; Finsterer, 2008; Guy et al., 2002).
Given the multi-systemic feature of mitochondrial cytopathies,
different pharmacological approaches are required, but most of the
proposed therapies are usually of scarce effectiveness (Zaffanello and
Zamboni, 2005).
Non-speciﬁc drug therapy consists of different pharmacological
agents, divided according to the type of action into antioxidants and
lactate lowering agents (which remove noxious metabolites),
electron transfer mediators (which bypass the defective site),Fig. 2. Schematic representation of mitochondrial dysfunctions in some common disease.
reduced extracellular Ca2+ inﬂux or Ca2+ release from stores) impairs Krebs cycle an
mitochondrial DNA mutations, leading to further malfunctioning of ETC. The resulting impai
Excessive mitochondrial Ca2+ uptake induces opening of PTP leading to well known tox
generation with consequent lipid perodxation and enhancement the probability of PTP openi
β-amyloid leads to ROS generation in neurons, causing cytosolic Ca2+ accumulation by differ
and PTP opening. Mitochondrial Ca2+ overload is also responsible for dopaminergic neuro
reduced mitochondrial Ca2+ uptake in mitochondrial primary diseases (MIDs). Mutation
generation, leading to impaired ATP synthesis and reduced Ca2+ accumulation. Because of t
reduced the ability of mitochondria to synthetize ATP affecting cell physiology and survivaalternative energy providers, cofactors, and other agents (Finsterer,
2010), such as Coenzyme Q10, ascorbic acid, vitamin E, lipoic acid,
riboﬂavin, thiamin, niacin, and vitamin K (phylloquinone and
menadione). The general objective is to increase mitochondrial ATP
production and to slow (or arrest) the progression of the clinical
symptoms (Marriage et al., 2003).
In order to correct the energy imbalance in MIDs, it would be
interesting to introduce drugs able to act on intracellular Ca2+
homeostasis since a strong relationship exists between Ca2+ and
mitochondrial ATP synthesis (see Fig. 2). Brieﬂy, Ca2+ is stored at a high
concentrationwithin theER. This Ca2+ content is activelymaintainedby
the sarcoplasmic/endoplasmic Ca2+ ATPase (SERCA) located on
membranes of the ER that constantly pump cytosolic Ca2+ into the
lumen, at the expense of ATP. This ATP is mostly provided by
mitochondria through the close contact sites between ER and
mitochondria (Giorgi et al., 2009).
It has been reported, especially for defects on respiratory complex
I, that cells from patients with mitochondrial diseases show reduced
mitochondrial membrane potential together with reduced ATP
synthesis. This causes a reduced mitochondrial Ca2+ uptake under
physiological stimulations (Visch et al., 2006). Since Ca2+ uptake by
mitochondria promotes Krebs cycle activity and ATP synthesis
(Jouaville et al., 1999), it could be hypothesized that a negative
feedback is created thatmaintains low intracellular Ca2+ levels and ATP
contents in cells derived fromMIDspatients. In this scenario, itwould be
interesting to study the molecules capable of increasing ER or
mitochondrial Ca2+ levels. It has already been proposed that the
pharmacological inhibition of themitochondrial sodium Ca2+ exchang-
er (that extrudes Ca2+ from mitochondria after physiological stimula-
tion, recovering the basal [Ca2+]) is able to restore mitochondrial ATP
synthesis in cells harboring mitochondrial DNA mutations (Brini et al.,
1999; Visch et al., 2004). Mitochondrial Ca2+ uptake is also a signaling
event in the apoptotic cascade, especially in oxidative stress conditions.
Indeed, sustained mitochondrial Ca2+ elevations are able to induce the
opening of the PTP, almost without stimulating the Krebs cycle.
Since oxidative stress appears to be a common feature in many
MIDs, therapeutical approaches based on Ca2+ handling should be
considered togetherwith antioxidant drugs or blockers of the PTP. The
latter, especially Cyclosporin A (CsA), are able to inhibit cytochrome c
release induced by a number of apoptotic stimuli (Ow et al., 2008;
Walter et al., 1998) and also increase the mitochondrial membrane
potential.
Cyclosporins are used as immunosuppressants (probably indepen-
dently from their mitochondrial activity) and diverse studies support a
protective role for CsA in diseases with associated mitochondrial
dysfunctions. Myoblasts from patients affected by Ullrich congenital
muscular dystrophy display several mitochondrial alterations and a
higher susceptibility to apoptosis due to the inappropriate opening of
the PTP. In these conditions, it has been observed that CsA inhibits
apoptosis engagement (Merlini et al., 2008).
5. Mitochondria as drug targets in the treatment of
cardiovascular diseases
Cardiovascular disease is the leading cause of morbidity and
mortality in the developed world. A multitude of recent studiesA. In pancreatic β cells, generalized reduction of mitochondrial Ca2+ uptake (due to
d electron transport chain (ETC) activity. Anomalous ROS production can generate
rment in ATP production brings to reduced β cell activity and reduced insulin release. B.
ic effects. Further excessive ion concentration impairs ETC efﬁciency promoting ROS
ng. C. Ca2+ overload induce cell death in neurons. In Alzheimer's disease the presence of
ent mechanisms. This homeostasis deregulation brings to mitochondrial Ca2+ overload
ns death in Parkinson's disease. D. Neuronal severe dysfunctions can be generated by
s in mtDNA are able to affect ETC and mitochondrial membrane potential and ROS
he Ca2+ dependency of some enzymes of Krebs cycle a positive feedback progressively
l.
81C. Giorgi et al. / Mitochondrion 12 (2012) 77–85suggest that mitochondria play critical roles in both the life and death
of terminally differentiated cardiac myocytes. Mitochondria malfunc-
tion has been implicated in various cardiac pathologies, including
ischemia–reperfusion (I/R) injury, cardiomyopathy, and congestive
heart failure (Gustafsson and Gottlieb, 2008).reduced 
Insulin Release
catalase &
SOD2 
2+Ca  channels
2+Ca
MCU
DV A
C
2+Ca
ROS
FADH2
mtDNA
reduced 
 cells Activity
NADH
A   Type I and II diabetes
C   Neurodegenerative diseases
Kr
eb
s
Cy
cle
ROS a eATP s
ETC
+H
+
H
FADH2
ADP
P+ i
ATP
NADH
Reduced proton 
transport
Reduced ATP
 syntesis
ROS
Lipid
Peroxidation
Lipid
Peroxidation
Reduced 
Calcium extrusion 
system activity
Amyloid 
Alzheim er’s 
dise ase
Calcium
Overload
L-type 
 channels2+Ca
Parkins on’s
dise ase
NMDAR Voltage-gated 
2+Ca  Channel
increased mutations,
reduced DNA stability
MCUV A
CD
reb
Cycle
K
s
AT aP se
+H
+
H
ETC
Reduced ATP
 syntesis
Impaired Calcium Influx
Reduced mitochondrial 
Calcium Uptake
Impaired Calcium stores
and Calcium release
DAV
C
PM
HK
BR CKMPTP Opening
CD
PPT
PM
ER
ERIn healthymyocytes, mitochondria occupy a large portion of the cell
and are located between the myoﬁbrils and just below the sarcolemma
(Andrienko et al., 2003). Pathophysiological conditions that can open
the PTP are characteristically present duringmyocardial I/R (Di Lisa and
Bernardi, 2006) (see Fig. 2). As such, an increasing number ofMCU
VDA
C
2+Ca
-180 mV
+
+
+
+
+
+
+
ROS
MCU
DV A
C
+H
+PADP i
TA P
-180 mV
+
+
+
+
+
+
+
Calcium
Overload
Ru Red;
Ru360
Bax
Bcl2
DNP,
FCCP
+K  channels
Diazoxide;
Nicorandil
Vitamin E;
Trans-Resveratrolo;
Gino Biloba extract;
MitoQ
CSA
6[N-methyl-ala ]CsA, 
4[N-methyl-Val ]CsA,
 Debio 025, NIM 811 
UNIL025
mtDNA
mutations
e
Cy
Kr
bs
cle
aseATP
TE C
+H
FADH2
NADH
C
Kr
eb
s
yc
le
ROS
a eATP s
ETC
+H
+
H
FADH2
PAD
+Pi
ATP
NADH
Reduced proton 
transport
Reduced ATP
 syntesis
Ischemia/Reperfusion
Cardiomyopathy
Heart failure
Infarction
B   Cardiovascular diseases
D   Mitochondrial I diseases (MIDs)
Reduced mitochondrial 
Calcium Uptake
VDA
C
ANT
HK
BR CKMPTP Opening
CD PT
P
VDA
C
NTA
HK
BR CK
CD PT
P
82 C. Giorgi et al. / Mitochondrion 12 (2012) 77–85pharmacological approaches are currently being developed to try to
interferewith theseparameters.One approach is basedon the inhibition
of Ca2+ overload. Cardioprotective effects of strategies that limit
mitochondrial Ca2+ accumulation, have been demonstrated (Miyamae
et al., 1996). For instance, treatment of hearts with ruthenium red (RR)
or Ru360, inhibitors of the Ca2+ uniporter, reduced infarct size in hearts
subjected to I/R (Garcia-Rivas Gde et al., 2006; Park et al., 1990). In
addition, Ru360 treatment dramatically decreased [Ca2+]m and inhib-
itedPTPopening,whichwasassociatedwith improved recovery of heart
performance (Goldberg and Bursey, 1992). Mitochondrial membrane
potential is another critical regulator of Ca2+ accumulation: depolari-
zation reduces the driving force for Ca2+ uptake by mitochondria and
thereby prevents Ca2+ overload; this prompted researchers to consider
the decrease of the potential as a possible mechanism of cellular
protection. This objective is attainedwith uncoupler agents such as 2-4-
dinitrophenol (DNP) and carbonyl cyanide p-(triﬂuoromethoxy)-
phenylhydrazone (FCCP) (Brennan et al., 2006), and mitochondrial
ATP-sensitive K+ (mitoKATP) channel openers, such as diazoxide
(Garlid et al., 1997; Iwai et al., 2000) or nicorandil, (Carreira et al.,
2008; Iwai et al., 2002), which showed a cardioprotective effect in
different models of I/R (Ishii et al., 2005; Kitakaze et al., 2007; Liu et al.,
1998). Pharmacological openers of the mitoKATP channel have been
developed for the treatment of angina pectoris (nicorandil) and
hypertension (cromakalim and pinacidil) (Grover et al., 2001; Yang
and Yu, 2010).
Cardiac mitoKATP channels were also identiﬁed as important
mediators of protection during ischemic preconditioning (IPC), the
most potent method for reducing reperfusion injury (Fryer et al.,
2000; Murry et al., 1986), and thus represent a promising drug target.
Oxidative stress has also been associated with loss of cells in heart
failure, I/R injury, and doxorubicin-induced cardiomyopathy, whereas
reducing ROS production is cardioprotective (Gustafsson and Gottlieb,
2008). Moreover, decreased antioxidant capacity and increased oxida-
tive stress are both related to heart failure. There is an increased
production of ROS in failing hearts after myocardial infarction and
consequently lipidperoxidation, decreaseofmtDNAcopynumber, and a
reduced oxidative capacity due to lower activity of electron transfer
enzymes (Ide et al., 2001). Antioxidants, such as Vitamin E (Sethi et al.,
2000), Ginkgo biloba extract (Seif-El-Nasr and El-Fattah, 1995), Trans-
resveratrol (Goh et al., 2007; Ray et al., 1999), that remove radicals from
cells, protect against I/R injury (Reeve et al., 2005). The use of novel
mitochondria-targeted antioxidants has gained much interest (Victor
and Rocha, 2007). Mitochondrial targeting is feasible by conjugating an
antioxidant to a lipophilic cation. MitoQ, based on the endogenous
mitochondrial ubiquinone coenzyme Q, is such a compound; a recent
study demonstrated that feeding rats with MitoQ signiﬁcantly limited
cardiac reperfusion injury (Adlam et al., 2005).
Moreover, inhibition of the PTP through direct targeting of its
putative components (i.e., the adenine nucleotide translocator (ANT)
and Cyclophilin D (CyP-D)) may represent an effective therapeutic
approach in protecting the heart against various cardiac pathologies
(reviewed in (Bernardi and Forte, 2007; Halestrap and Pasdois, 2009)).
CsA has been demonstrated to be cardioprotective in isolated
cardiomyocytes subjected to anoxia and reoxygenation (Grifﬁths
et al., 2000; Nazareth et al., 1991), in Langendorff-perfused hearts
subjected to global I/R (Grifﬁths and Halestrap, 1993), as well as
in animals subjected to coronary artery ligation and reperfusion
(Hausenloy et al., 2003). One problem with the use of CsA is that it
can induce additional effects through inhibition of the Ca2+-regulated
proteinphosphatase calcineurin, thathasdirect effects onheart function
(Periasamy, 2002) and also undesirable immunosuppressive activity
(Schreiber and Crabtree, 1992). To overcome this, other cyclosporine
derivatives, such as the immunosuppressant sanglifehrin A (SfA), as
well as non-immunosuppressants [N-methyl-ala6]CsA, [N-methyl-Val4]
CsA, Debio 025, NIM 811 and UNIL025, were found to exhibit similar
properties in terms of blocking pore opening, while being devoid ofcalcineurin inhibitory activity (Clarke et al., 2002; Gomez et al., 2007;
Javadov et al., 2009). In addition, studies on isolated mitochondria and
cultured cardiomyocytes have conﬁrmed a protective role of the ANT
inhibitor bongkrekic acid, via inhibition of pore opening (Akao et al.,
2003). Recently, Schaller et al., (2010) have discovered a new
mitochondrial-targeted cardioprotective drug, TRO40303 (3,5-Seco-4-
nor-cholestan-5-one oxime-3-ol), that binds speciﬁcally to the mito-
chondrial translocator protein (TSPO, formerly known as Peripheral
Benzodiazepine Receptor) and inhibits PTP opening triggered by
oxidative stress. Another interesting result was obtained with the free
radical scavenger edavarone, which was shown to inhibit PTP opening
and to prevent cardiac reperfusion injury (Tsujita et al., 2006).
Finally, the Bcl-2 family proteins, which control mitochondrial
membrane permeabilization and Ca2+ homeostasis, also play a central
role in regulating apoptosis in the cardiovascular system (Gustafsson
andGottlieb, 2007).Many of the pro-apoptotic Bcl-2 proteins have been
implicated in the pathogenesis of various cardiac diseases, including
myocardial hypertrophy, infarction, and heart failure (Condorelli et al.,
1999; Jung et al., 2001). As such, anti-apoptotic interventions targeting
theBcl-2protein family provideopportunities forpossible anti-ischemic
therapies (Reed, 2001), either through a gain of anti-apoptotic function
or loss of pro-apoptotic function. The pharmacological strategy
inhibiting mitochondrial outer membrane permeability, and thus
apoptosis, by manipulation of the Bcl-2 family to protect the
myocardium against I/R injury is very recent but has already provided
interesting results (Hetz et al., 2005), supporting the idea that clinical
beneﬁts may be obtained in the near future.
From the above-described evidence, therapeutic interventions
designed to prevent mitochondrial damage hold major promise as a
novel strategy for reducing cardiac injury, the leading cause of death
in western societies. Effective therapies developed along these lines
will thus represent a major advance in health care.6. Mitochondria, Ca2+ dyshomeostasis and diabetes
Diabetes mellitus is a disorder resulting from defects of both insulin
secretion and action. To date, the cellular pathophysiology of diabetes-
induced impairments, remain controversial. Conceptually, the leading
mechanism driving cellular pathology is believed to be associated with
the accumulation of extracellular glucose, and generation of ROS,
thereby triggering pathological outcomes. There is abundant evidence
suggesting a central role of mitochondria in diabetes, insulin resistance,
insulin secretion and in complications derived from diabetes (Patti and
Corvera, 2010). However, it is still difﬁcult (and controversial) to
establish whether the alterations in mitochondrial function are the
cause or the effect of the disease. Typically, the number and size of
mitochondria is reduced in the muscle of diabetics, there is reduced
mitochondrial biogenesis and switching of metabolic substrate use that
is linked directly to mitochondrial enzymes (Chabi et al., 2005).
Mitochondria are an integral part of the insulin system found in the
islet cells of the pancreas. Ultrastructural examination of β-cells has
suggested that mitochondria are often in close proximity to the
secretory insulin granules. This may facilitate metabolism–secretion
coupling, as ATP is a major permissive factor for movement of insulin
granules and for priming of exocytosis (Maechler andWollheim, 2001).
When blood glucose is high, the rate of glycolysis in β-cells will increase
and, as a consequence, the ATP production is accelerated to provide the
energy for insulin exocytosis. Glucose-stimulated insulin release from
β-cells involves a complex series of signaling pathways. As in other
exocytotic fusion events, Ca2+ is an essential trigger of insulin granule
exocytosis (Rorsman and Renstrom, 2003). The Ca2+ signal resulting
from mitochondrial activation completes the chain of events between
glucose uptake into β-cells and insulin exocytosis. A common motif in
these cascades is the elevation of intracellular Ca2+ both in the cytosol
and within the mitochondria.
83C. Giorgi et al. / Mitochondrion 12 (2012) 77–85Mitochondria take up Ca2+ through the mitochondrial Ca2+
uniporter in response to the glucose-induced rise in cytoplasmic Ca2+,
and release Ca2+ through the mNCX (Bernardi, 1999a).
[Ca2+]c rises may originate from Ca2+ inﬂux at the plasma
membrane or Ca2+ mobilization from the ER. Local Ca2+ inﬂux or
mobilization creates microdomains, local increases of Ca2+ exceeding
the bulk [Ca2+] in the cytosol (Giorgi et al., 2009). For both pathways,
the amplitude and the duration of the [Ca2+]c rise may determine to
what extent β-cell mitochondria are activated. Depending on the
combination of secretagogues, the number and localization of such
Ca2+ domains most certainly vary (Rizzuto and Pozzan, 2006; Rutter
et al., 2006).
The diabetic state is related to mitochondrial dysfunction and
generally characterized by insufﬁcient supply of energy or defects in
the insulin signaling pathway.
It has been shown that a reduction in mitochondrial Ca2+
accumulation is responsible for a reduction in insulin secretion
(Wiederkehr and Wollheim, 2008), suggesting that modulation of
mitochondrial Ca2+ may be a therapeutic target.
Restorationof themitochondrial Ca2+ signal usingan inhibitor of the
mNCEwas shown to improve ATP generation and insulin secretion (Lee
et al., 2003; Visch et al., 2004), highlighting the exchanger as a potential
new target for diabetes drug discovery.
Among the most convincing links between mitochondrial dysfunc-
tion and diabetes are the observed point mutation in mtDNA. Indeed,
diabetes mellitus is very common in patients affected bymitochondrial
diseases (also referred to as mitochondrial encephalomyopathies,
characterized by genetic disorders of mtDNA, such as MERRF and
MELAS), while and amaternally-inherited formof diabetes is associated
tomtDNAmutations (Ballinger et al., 1992).Accordingly,with the above
suggested pivotal role of Ca2+ homeostasis in the cellular pathogenesis
of diabetes, agonist-induced Ca2+ rises and ATP generation were
blunted and could be restored by applying an inhibitor of the
mitochondrial Ca2+ efﬂux (Brini et al., 1999).
Finally, but not less important, an abnormal Ca2+ homeostasis and
impaired mitochondrial function have also been linked to neurological
complications associated with diabetes. Diabetic conditions affect ER
Ca2+ homeostasis in sensory neurons by lowering the ER Ca2+ content
due to reduced SERCA pump activity, inducing a mild condition of ER
stress that results in the decrease of nerve conductance velocity
(Verkhratsky and Fernyhough, 2008).
In conclusion, the signaling mechanisms that decode changes in
nutrient supply are complex and not completely understood, but a
control in intracellular [Ca2+], in particular at the mitochondrial level,
appears to be of great signiﬁcance for further research.
7. Conclusions
Mitochondria are the powerhouse of the cell being the place where
oxidative metabolism takes place, rendering mitochondria crucial both
in health anddisease.Many (if not all) of themitochondrial activities are
driven in a Ca2+-dependent manner. The biochemical properties of the
proteins involved inmitochondrial Ca2+ homeostasis have been known
for over four decades, but only recently have we begun to unravel the
dynamics of this cation at the molecular and mechanistic levels
(Hajnoczky and Csordas, 2010). Currently, speciﬁc drugs that act on
mitochondrial Ca2+ homeostasis are being developed and these may
open theway to new biochemically designed therapeutic approaches in
the treatment of several disorders.
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